Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · March 18, 2013

Rivaroxaban 2.5mg Shows Strong Mortality Benefit Following STEMI

Journal of the American College of Cardiology

 

Additional Info

Journal of the American College of Cardiology
Rivaroxaban in Patients Stabilized After a ST-Elevation Myocardial Infarction: Results From the ATLAS ACS 2-TIMI 51 Trial
J Am Coll Cardiol 2013 Mar 06;[EPub Ahead of Print], JL Mega, E Braunwald, SA Murphy, et al

Further Reading